Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01657331(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN + Benda) (NCT01657331)

Trial Description
This is a Phase I/II multicenter study to assess the safety and effectiveness of brentuximab vedotin (also known as SGN-035) and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial treatment(s). Patients will be accrued at Columbia University Medical Center (CUMC) and at two subsites in Canada.

In this trial, brentuximab vedotin will be given to patients on day 1 of each 21 day cycle and bendamustine will be given to patients on days 1 AND 2 of each 21 day cycle. Days 3-21 will be for rest.

This trial is sponsored by Owen A. O’Connor/Columbia University. [1]

Study Data

Study Schematic

Screen Shot 2016-07-06 at 4.34.16 PM


Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar